Joseph A. Ludwig

10.7k total citations · 2 hit papers
93 papers, 7.8k citations indexed

About

Joseph A. Ludwig is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joseph A. Ludwig has authored 93 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Joseph A. Ludwig's work include Sarcoma Diagnosis and Treatment (49 papers), Cardiac tumors and thrombi (12 papers) and Lymphoma Diagnosis and Treatment (11 papers). Joseph A. Ludwig is often cited by papers focused on Sarcoma Diagnosis and Treatment (49 papers), Cardiac tumors and thrombi (12 papers) and Lymphoma Diagnosis and Treatment (11 papers). Joseph A. Ludwig collaborates with scholars based in United States, Germany and Hungary. Joseph A. Ludwig's co-authors include John N. Weinstein, Michael M. Gottesman, Gergely Szakács, Catherine Booth-Genthe, Robert S. Benjamin, Antonios G. Mikos, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Alexander J. Lazar and Pete Anderson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joseph A. Ludwig

89 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting multidrug resistance in cancer

2006 3.0k citations Gergely Szakács, Joseph A. Ludwig et al. profile →
Biomarkers in Cancer Staging, Prognosis and Treatment Selection

2005 1.3k citations Joseph A. Ludwig et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph A. Ludwig United States	34	3.3k	3.3k	1.7k	1.1k	1.0k	93	7.8k
Giuseppe Toffoli Italy	46	3.9k 1.2×	3.1k 1.0×	922 0.6×	1.0k 0.9×	1.1k 1.1×	337	8.8k
Joel M. Reid United States	51	4.5k 1.3×	3.0k 0.9×	1.6k 1.0×	548 0.5×	958 0.9×	270	10.0k
Michael G. Walker United Kingdom	45	3.0k 0.9×	2.9k 0.9×	1.5k 0.9×	524 0.5×	3.6k 3.5×	158	10.2k
Go Watanabe Japan	51	3.3k 1.0×	2.5k 0.8×	2.5k 1.5×	521 0.5×	868 0.8×	515	9.9k
Sunil Krishnan United States	55	1.8k 0.5×	3.7k 1.1×	2.9k 1.7×	1.0k 0.9×	1.3k 1.2×	197	9.1k
Carlos M. Galmarini Spain	41	3.2k 1.0×	2.5k 0.8×	1.0k 0.6×	778 0.7×	1.2k 1.1×	155	7.0k
Clemens Unger Germany	52	4.1k 1.2×	2.6k 0.8×	1.2k 0.7×	549 0.5×	1.1k 1.0×	202	8.1k
Nadia Zaffaroni Italy	57	8.0k 2.4×	3.8k 1.2×	1.8k 1.0×	809 0.7×	2.8k 2.7×	351	13.0k
Hirohisa Yano Japan	43	3.1k 0.9×	2.4k 0.7×	974 0.6×	437 0.4×	1.7k 1.7×	283	8.0k
Dietmar W. Siemann United States	53	4.2k 1.3×	2.5k 0.8×	1.5k 0.9×	1.2k 1.1×	2.7k 2.6×	276	8.9k

Countries citing papers authored by Joseph A. Ludwig

Since Specialization

Citations

This map shows the geographic impact of Joseph A. Ludwig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph A. Ludwig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph A. Ludwig more than expected).

Fields of papers citing papers by Joseph A. Ludwig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph A. Ludwig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph A. Ludwig. The network helps show where Joseph A. Ludwig may publish in the future.

Co-authorship network of co-authors of Joseph A. Ludwig

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph A. Ludwig. A scholar is included among the top collaborators of Joseph A. Ludwig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph A. Ludwig. Joseph A. Ludwig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chiang, Yi‐Ju, Anthony P. Conley, Dejka M. Araujo, et al.. (2024). Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST).. Journal of Clinical Oncology. 42(16_suppl). 11583–11583. 1 indexed citations

Meyers, Paul A., Noah Federman, Najat C. Daw, et al.. (2024). Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. Journal of Clinical Oncology. 42(31). 3725–3734. 13 indexed citations

Truong, Danh D., et al.. (2024). Abstract 2851: Characterization of neogenes in desmoplastic small round cell tumors. Cancer Research. 84(6_Supplement). 2851–2851. 1 indexed citations

Truong, Danh D., Salah-Eddine Lamhamedi-Cherradi, Mayinuer Maitituoheti, et al.. (2023). Abstract 1196: The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT. Cancer Research. 83(7_Supplement). 1196–1196. 1 indexed citations

Wu, Chia-Chin, Hannah C. Beird, Salah-Eddine Lamhamedi-Cherradi, et al.. (2022). Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. npj Precision Oncology. 6(1). 21–21. 13 indexed citations

Lamhamedi-Cherradi, Salah-Eddine, Dhruva K. Mishra, David McCall, et al.. (2021). Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy. 28(12). 1325–1338. 25 indexed citations

Ludwig, Joseph A., et al.. (2020). Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. Tissue Engineering Part B Reviews. 26(3). 249–271. 29 indexed citations

Tarek, Nidale, Rabih Said, Clark R. Andersen, et al.. (2020). Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers. 12(10). 2927–2927. 12 indexed citations

Subbiah, Vivek, Pete Anderson, Kalevi Kairemo, et al.. (2019). Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research. 25(13). 3802–3810. 32 indexed citations

10.

Koons, Gerry L., Brian A. Menegaz, Salah-Eddine Lamhamedi-Cherradi, et al.. (2019). 3D Tissue-Engineered Tumor Model for Ewing’s Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomaterials Science & Engineering. 6(1). 539–552. 21 indexed citations

11.

Subbiah, Vivek, Salah-Eddine Lamhamedi-Cherradi, Branko Cuglievan, et al.. (2018). Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clinical Cancer Research. 24(19). 4865–4873. 61 indexed citations

12.

Trachtenberg, Jordan E., Marco Santoro, Charlotte Piard, et al.. (2017). Effects of Shear Stress Gradients on Ewing Sarcoma Cells Using 3D Printed Scaffolds and Flow Perfusion. ACS Biomaterials Science & Engineering. 4(2). 347–356. 34 indexed citations

13.

Santoro, Marco, Brian A. Menegaz, Salah-Eddine Lamhamedi-Cherradi, et al.. (2016). Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. Tissue Engineering Part A. 23(1-2). 80–89. 26 indexed citations

14.

Lamhamedi-Cherradi, Salah-Eddine, Brian A. Menegaz, Vandhana Ramamoorthy, et al.. (2015). An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma. Molecular Cancer Therapeutics. 14(7). 1591–1604. 33 indexed citations

15.

Satelli, Arun, Abhisek Mitra, Jeffry J. Cutrera, et al.. (2014). Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research. 74(6). 1645–1650. 131 indexed citations

16.

Lamhamedi-Cherradi, Salah-Eddine, Marco Santoro, Brian A. Menegaz, et al.. (2014). 3D tissue-engineered model of Ewing's sarcoma. Advanced Drug Delivery Reviews. 79-80. 155–171. 39 indexed citations

17.

Naing, Aung, Patricia LoRusso, Siqing Fu, et al.. (2012). Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. Clinical Cancer Research. 18(9). 2625–2631. 163 indexed citations

18.

Kasper, F. Kurtis, et al.. (2010). Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology. Tissue Engineering Part B Reviews. 16(3). 351–359. 145 indexed citations

19.

Türk, Dóra, Matthew D. Hall, Benjamin F. Chu, et al.. (2009). Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells. Cancer Research. 69(21). 8293–8301. 87 indexed citations

20.

Garlichs, Christoph D., Suzanne Fateh‐Moghadam, Bernd Tomandl, et al.. (2003). Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia. Stroke. 34(6). 1412–1418. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact